Form 4: Unicycive Therapeutics CFO John Townsend Reports Stock Option Grant

John Townsend, CFO of Unicycive Therapeutics, reports the acquisition of stock options.

Summary

• On August 12, 2024, John Townsend, the Chief Financial Officer of Unicycive Therapeutics, acquired 40,256 stock options with an exercise price of $0.34.
• These options vest over time, with 10,064 vesting on August 12, 2025, and the remainder vesting monthly over the following three years.
• Following this transaction, Townsend directly owns 915,565 shares of Unicycive Therapeutics common stock.
• The options expire on August 12, 2034.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is slightly positive due to the incentive provided to the CFO.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their compensation packages to align executive incentives with shareholder value.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates